What is Eli Lilly’s Verzenio (abemaciclib)?
Verzenio is a cancer medicine made by Eli Lilly. It contains the active ingredient abemaciclib and is used to treat certain hormone receptor–positive (HR+), HER2-negative advanced or metastatic breast cancers, often in combination with endocrine (hormone-blocking) therapy and sometimes with other drugs depending on the disease stage and prior treatment history.
What kinds of breast cancer does Verzenio treat?
Verzenio’s use depends on where the cancer is in its course (for example, early vs. advanced/metastatic) and prior treatments, but it is specifically aimed at HR+/HER2- breast cancer settings that require CDK4/6 pathway inhibition (abemaciclib is a CDK4/6 inhibitor).
How is Verzenio typically taken?
Verzenio is an oral therapy (a tablet taken by mouth). Exact dosing and whether it’s used alone or with other medications depend on the specific indication and patient factors.
What side effects do patients ask about most?
Commonly discussed side effects for CDK4/6 inhibitors like abemaciclib include gastrointestinal effects (especially diarrhea), as well as fatigue and low blood counts. The specific risk profile can vary based on other medicines used with Verzenio and how patients respond to treatment.
Who makes Verzenio and are there patent or exclusivity issues?
Verzenio is associated with Eli Lilly. If you’re looking at future generic or biosimilar-like competition (or when challengers may file), DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can help you see what is still protected and what may be expiring.
Source: DrugPatentWatch.com: Verzenio (abemaciclib) patents
How do people choose Verzenio vs other CDK4/6 inhibitors?
In HR+/HER2- breast cancer, Verzenio is one option among CDK4/6 inhibitors (others include palbociclib and ribociclib). Selection often depends on the exact treatment line, combination plan (with endocrine therapy and/or other agents), and tolerability (for example, how patients handle diarrhea and blood count changes).
Can Verzenio be used with endocrine therapy?
Yes. Verzenio is commonly paired with endocrine therapy in HR+/HER2- disease, with the specific combination determined by the clinical setting and prior treatments.
Sources
- DrugPatentWatch.com: Verzenio (abemaciclib)